CN103739537B - New synthesis method of ezetimibe - Google Patents

New synthesis method of ezetimibe Download PDF

Info

Publication number
CN103739537B
CN103739537B CN201310722140.5A CN201310722140A CN103739537B CN 103739537 B CN103739537 B CN 103739537B CN 201310722140 A CN201310722140 A CN 201310722140A CN 103739537 B CN103739537 B CN 103739537B
Authority
CN
China
Prior art keywords
milliliters
formula
add
grams
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310722140.5A
Other languages
Chinese (zh)
Other versions
CN103739537A (en
Inventor
杨宝海
潘必高
付勇
陈星汶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lianyungang Hengyun Pharmaceutical Co. Ltd.
Original Assignee
LIANYUNGANG HENGYUN MEDICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIANYUNGANG HENGYUN MEDICAL TECHNOLOGY Co Ltd filed Critical LIANYUNGANG HENGYUN MEDICAL TECHNOLOGY Co Ltd
Priority to CN201310722140.5A priority Critical patent/CN103739537B/en
Publication of CN103739537A publication Critical patent/CN103739537A/en
Application granted granted Critical
Publication of CN103739537B publication Critical patent/CN103739537B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

The invention relates to a new synthesis method of ezetimibe. Particularly, a new method for synthesizing ezetimibe (as shown in formula (I)) comprises the steps of addition, closed loop, deprotection and the like by using a compound shown in a formula (II) and having good stability as a starting raw material. The new synthesis method has the advantages of strong stability, simple operation, high yield and the like, and is suitable for large-scale industrial production. The formula (I) is described in the specification.

Description

The novel synthesis of Ezetimibe
Technical field
The present invention relates to pharmaceutical synthesis field, be specifically related to the novel synthesis of Ezetimibe and 1-(4-fluorophenyl)-3 (R)-[3-(4-fluorophenyl)-3 (S)-hydroxypropyl]-4 (S)-(4-hydroxyphenyl)-2-azetidinone.
Background technology
Ezetimibe (Ezetimibe) as shown in the formula (I), another name ezetimibe, Zetia, for the first selectivity cholesterol absorption inhibitor that Schering Plough (Schering-Plough) company and Merck (Merck) company develop jointly, this product is first cholesterol absorption selective depressant class medicine be approved listing by U.S. FDA, trade(brand)name Zetia.This product obtains FDA approval on October 25th, 2002, and goes on the market on November 30th, 2002 in the U.S..At present, the indication that Ezetimibe obtains FDA approval has primary hypercholesterolemia (adult, paediatrics) homozygous familial hypercholesterolemia (adult, paediatrics), homozygous familial Sitosterolemia (adult, paediatrics), mixed type hyperlipidemia (adult).
European patent EP 720599 makes public for the first time the synthetic method of Ezetimibe:
This operational path is longer, employs active metal reagent and precious metal palladium, and gained midbody compound is unfavorable for purifying, and cost is higher, is not suitable for suitability for industrialized production.
Schering Plough company of the U.S. is optimized above-mentioned technique, discloses a kind of method of synthesis Ezetimibe newly in patent WO2000/34240:
This route has carried out larger improvement to technique in early stage: chiral reduction obtains chiral alcohol, protects in next step asymmetric Mannich reaction, and adopt TMSCl to protect one pot process intermediate, then Cheng Huan, deprotection prepare Ezetimibe finished product.But the asymmetric Mannich reaction in route due to intermediate character active, cause byproduct of reaction more, yield is lower, limits its application in suitability for industrialized production.
Summary of the invention
The object of this invention is to provide a kind of simple to operate, yield is high and the novel method of the synthesis Ezetimibe of applicable suitability for industrialized production.
Another object of the present invention is to the method providing a kind of preparation formula (I) compound, it comprises the following steps:
A) formula (III) compound and chlorosilane protect reagent to react under the existence of organic bases, the compound of obtained protected silane, then add formula (II) compound and Lewis acid, react, obtain formula (IV) compound under the existence of Lewis acid and organic bases,
B) formula (IV) compound cyclization under the existence of silane reagent and fluoride ion catalyst, obtains formula V compound,
Wherein, in formula (II), formula (IV) and formula V compound, R is selected from C 1-C 3alkyl, phenyl; Optional, described phenyl can be selected from alkyl further, the substituting group of alkoxyl group replaces;
C) formula V compound removes acyl group and silane protecting group, obtains Ezetimibe as shown in the formula (I),
Preferably, organic bases described in step a) is diisopropylethylamine.
Preferably, described in step b), silane reagent is selected from N, the two trimethylsilyl ethanamide of O-or trimethyl silane.
Preferably, fluoride ion catalyst described in step b) is three hydration tetrabutyl ammonium fluorides.
Preferably, acyl group and protected silane base group employing protonic acid solution is removed described in step c); Preferred, described protonic acid is selected from hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid; Be particularly preferably sulfuric acid.
Another object of the present invention is also to provide a kind of such as formula the intermediate preparing Ezetimibe shown in (IV),
Wherein, R is methyl.
Another object of the present invention is also to provide a kind of intermediate preparing Ezetimibe as shown in formula V,
Wherein, R is methyl.
The present invention, by adopting acyl group protection to the alcoholic extract hydroxyl group of formula (II) compound, makes its difficult drop-off in reaction process, the corresponding activity that improve other reactive groups, contributes to the yield improving reaction.In addition, preparation technology of the present invention reacts less demanding, simple to operate, is easy to purifying, such that the preparation of Ezetimibe is more economical, more environmental protection, be more suitable for industrialization.
Embodiment
In order to understand content of the present invention better, below in conjunction with specific embodiment, the invention will be further described, but scope of the present invention is not limited to specific embodiment.
Embodiment 1: the preparation of Ezetimibe intermediate formula (IV) compound
At N 2under, add 150 milliliters of methylene dichloride and 21.5 grams of formula (III) compounds, stir and be cooled to-20 DEG C.Add 30.6 milliliters of diisopropylethylamine (DIPEA); Slow dropping 16.1 milliliters of trimethylchlorosilanes (TMSCl), keep temperature-15 DEG C to stir 1.5 hours.Reaction solution is cooled to-30 DEG C and adds 20.0 grams of formula (II) compounds, stir 10 minutes.Slow dropping 4.1 milliliters of TiCl 4, keep temperature-30 DEG C of stirring reactions 4 hours.Slowly water is added in reaction mixture, cancellation is reacted, add 60 milliliters of 1N aqueous hydrochloric acids, add 200 milliliters of methylene dichloride, stratification after stirring, organic layer is washed, anhydrous sodium sulfate drying, be concentrated into a small amount of solvent, add 15 milliliters of two trimethyl silane yl acetamides, reflux 30 minutes.Enriched mixture, removing methylene dichloride, makes product crystallization in ethyl acetate and normal heptane mixed solvent, and filter, 30 DEG C of vacuum-dryings, obtain product 27.1 grams, yield 79.1%.
Embodiment 2: the preparation of Ezetimibe intermediate formula V compound
Under nitrogen protection, add 300 milliliters of methyl tertiary butyl ethers and 20 grams of formula (II) compounds, add the two trimethylsilyl ethanamide (BSA) of 14.3 milliliters of N, O-, control temperature 10 DEG C.Add 0.48 gram of tetrabutyl ammonium fluoride (three water) (TBAF), stirring reaction 2 hours.Mixture is concentrated into dry, directly enters next step.
Embodiment 3: the preparation of Ezetimibe
In the product in embodiment 2, add 50 milliliters of Virahols and 15 milliliters of 2N sulphuric acid solns, stirred at ambient temperature 2 hours, separate out solid, filter, collect solid, in isopropyl alcohol and water, obtain white solid after recrystallization, target product formula (I) compound 14.54 grams is obtained, yield 93% after drying.
MS(ESI):432.14(M+Na +).
1H-NMR(500MHz,DMSO)δ(ppm):1.761-1.804(m,3H),1.823-1.889(m,1H),3.079-3.101(m,1H),4.514-4.535(m,1H),4.804-4.808(d,1H),5.263-5.272(d,1H),6.772-6.789(d,2H),7.099-7.141(m,4H),7.218-7.249(m,4H),7.306-7.334(m,2H),9.504(s,1H).

Claims (1)

1. a method for preparation formula (I) compound, it comprises the following steps:
a)
At N 2under, add 150 milliliters of methylene dichloride and 21.5 grams of formula (III) compounds, stir and be cooled to-20 DEG C, add 30.6 milliliters of diisopropylethylamine; Slow dropping 16.1 milliliters of trimethylchlorosilanes, keep temperature-15 DEG C to stir 1.5 hours, reaction solution are cooled to-30 DEG C and add 20.0 grams of formula (II) compounds, stir 10 minutes, slowly drip 4.1 milliliters of TiCl 4keep temperature-30 DEG C of stirring reactions 4 hours, in reaction mixture, slowly add water, cancellation is reacted, and adds 60 milliliters of 1N aqueous hydrochloric acids, add 200 milliliters of methylene dichloride, stratification after stirring, organic layer is washed, anhydrous sodium sulfate drying, be concentrated into a small amount of solvent, add 15 milliliters of two trimethyl silane yl acetamides, reflux 30 minutes, enriched mixture, removing methylene dichloride, make product crystallization in ethyl acetate and normal heptane mixed solvent, filter, 30 DEG C of vacuum-dryings, obtain product 27.1 grams, yield 79.1%;
B) under nitrogen protection, add 300 milliliters of methyl tertiary butyl ethers and 20 grams of formula (IV) compounds, add 14.3 milliliters of N, the two trimethylsilyl ethanamide of O-, control temperature 10 DEG C, adds 0.48 gram of three water tetrabutyl ammonium fluoride, stirring reaction 2 hours, mixture is concentrated into dry, directly enters next step;
C) in the product of previous step, 50 milliliters of Virahols and 15 milliliters of 2N sulphuric acid solns are added, stirred at ambient temperature 2 hours, separate out solid, filter, collect solid, in isopropyl alcohol and water, obtain white solid after recrystallization, obtain target product formula (I) compound 14.54 grams after drying, yield 93%;
Wherein, in formula (II), formula (IV) and formula (V) compound, R is methyl.
CN201310722140.5A 2013-12-24 2013-12-24 New synthesis method of ezetimibe Active CN103739537B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310722140.5A CN103739537B (en) 2013-12-24 2013-12-24 New synthesis method of ezetimibe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310722140.5A CN103739537B (en) 2013-12-24 2013-12-24 New synthesis method of ezetimibe

Publications (2)

Publication Number Publication Date
CN103739537A CN103739537A (en) 2014-04-23
CN103739537B true CN103739537B (en) 2015-05-20

Family

ID=50496625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310722140.5A Active CN103739537B (en) 2013-12-24 2013-12-24 New synthesis method of ezetimibe

Country Status (1)

Country Link
CN (1) CN103739537B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461649B (en) * 2014-08-08 2019-10-22 浙江九洲药业股份有限公司 A kind of Ezetimible intermediate and preparation method thereof
CN106892851A (en) * 2017-03-09 2017-06-27 上海华源医药科技发展有限公司 A kind of new method for preparing Ezetimibe crystal formation I
CN112441959A (en) * 2020-12-07 2021-03-05 石家庄市华新药业有限责任公司 Ezetimibe raw material medicine synthesis process
CN114621126B (en) * 2020-12-12 2023-07-25 重庆圣华曦药业股份有限公司 Improved ezetimibe preparation method

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131416A (en) * 1993-09-21 1996-09-18 先灵公司 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997045406A1 (en) * 1996-05-31 1997-12-04 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
CN1329592A (en) * 1998-12-07 2002-01-02 先灵公司 Process for synthesis of beta-propanamide
WO2007072088A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Process for the production of ezetimibe and intermediates used in this proces
CN101423511A (en) * 2007-11-05 2009-05-06 中山奕安泰医药科技有限公司 Ezetimible intermediate and synthetic method of ezetimible
CN101935309A (en) * 2009-06-29 2011-01-05 上海特化医药科技有限公司 Method for preparing ezetimibe and intermediate thereof
US20110046389A1 (en) * 2008-02-25 2011-02-24 Hana Stepankova Intermediates for the preparation of (3r, 4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
CN102234246A (en) * 2010-04-23 2011-11-09 浙江华海药业股份有限公司 Novel ezetimibe synthesis method
WO2012004382A1 (en) * 2010-07-09 2012-01-12 Moehs Iberica S.L. New method for preparing ezetimibe
CN102850390A (en) * 2011-07-01 2013-01-02 江苏豪森药业股份有限公司 Intermediate of ezetimibe and its preparation method
CN103102297A (en) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 Synthesis method of novel atorvastatin
CN103450065A (en) * 2013-07-15 2013-12-18 和鼎（南京）医药技术有限公司 Preparation method of ezetimibe

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131416A (en) * 1993-09-21 1996-09-18 先灵公司 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997045406A1 (en) * 1996-05-31 1997-12-04 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
CN1329592A (en) * 1998-12-07 2002-01-02 先灵公司 Process for synthesis of beta-propanamide
WO2007072088A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Process for the production of ezetimibe and intermediates used in this proces
CN101423511A (en) * 2007-11-05 2009-05-06 中山奕安泰医药科技有限公司 Ezetimible intermediate and synthetic method of ezetimible
US20110046389A1 (en) * 2008-02-25 2011-02-24 Hana Stepankova Intermediates for the preparation of (3r, 4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
CN101935309A (en) * 2009-06-29 2011-01-05 上海特化医药科技有限公司 Method for preparing ezetimibe and intermediate thereof
CN102234246A (en) * 2010-04-23 2011-11-09 浙江华海药业股份有限公司 Novel ezetimibe synthesis method
WO2012004382A1 (en) * 2010-07-09 2012-01-12 Moehs Iberica S.L. New method for preparing ezetimibe
CN102850390A (en) * 2011-07-01 2013-01-02 江苏豪森药业股份有限公司 Intermediate of ezetimibe and its preparation method
CN103102297A (en) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 Synthesis method of novel atorvastatin
CN103450065A (en) * 2013-07-15 2013-12-18 和鼎（南京）医药技术有限公司 Preparation method of ezetimibe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ezetimibe合成路线图解;蔡正艳,等;《中国医药工业杂志》;20040420;第35卷(第04期);第251-253页 *
依折麦布中间体的合成工艺研究;蔡金刚,等;《精细化工中间体》;20110831;第41卷(第04期);第37-39页 *

Also Published As

Publication number Publication date
CN103739537A (en) 2014-04-23

Similar Documents

Publication Publication Date Title
CN105153010B (en) The preparation method of HMG-CoA reductase inhibitor and its intermediate
CN103739537B (en) New synthesis method of ezetimibe
WO2007004028A2 (en) Processes for the preparation of penems and its intermediate
CN104356129A (en) Novel method for producing tiotropium salts
CN104402790A (en) Improved method for preparing ezetimibe
Sá et al. Synthesis of allylic thiocyanates and novel 1, 3-thiazin-4-ones from 2-(bromomethyl) alkenoates and S-nucleophiles in aqueous medium
CN104447451B (en) New preparation method of oseltamivir intermediate
CN102002066A (en) Synthesis method of 4-acetoxyl-2-azetidinone
CN102336696A (en) Intermediate for synthesizing 4-AA and preparation method and application thereof
CN104829511A (en) Synthesizing process of Ezetimibe
CN102234246A (en) Novel ezetimibe synthesis method
WO2016045416A1 (en) Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof
CN102219803B (en) Preparation method of ezetimibe intermediate
CN103012331A (en) Preparation method of cabazitaxel and intermediate thereof
CN103059046B (en) Preparation method of faropenem
EP4249462A1 (en) Method for producing ketone derivative
CN103130753A (en) Semi-synthesis method of antitumor drug taxol
CN102174047A (en) Novel process for preparing doripenem
CN102367216A (en) Preparation method of diselenoaminoformate derivatives
CN107118144B (en) Reduction preparation process of ezetimibe and intermediate thereof
CN105348212A (en) Preparation method for Linezolid
CN113651847B (en) Process for producing azetidinone compound and process for producing 4-acyloxy azetidinone compound
CN102757398A (en) Preparation method of oxazolidinone derivatives
CN113527277B (en) Method for producing luliconazole and hydrochloride thereof
CN105037348B (en) A kind of Retapamulin synthetic method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: Zhang Qingjie

Inventor after: Yang Baohai

Inventor after: Pan Bigao

Inventor after: Fu Yong

Inventor after: Chen Xingmen

Inventor before: Yang Baohai

Inventor before: Pan Bigao

Inventor before: Fu Yong

Inventor before: Chen Xingmen

COR Change of bibliographic data
TR01 Transfer of patent right

Effective date of registration: 20170527

Address after: 222200 Guanyun City, Jiangsu province Lingang Industrial Zone, the south side of the weft Road, eight

Patentee after: Lianyungang Hengyun Pharmaceutical Co. Ltd.

Address before: 222200 Jiangsu city of Lianyungang province Guanyun County Harbor Industrial Zone weft seven road No. 1

Patentee before: LIANYUNGANG HENGYUN MEDICAL TECHNOLOGY CO., LTD.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 222200 Guanyun City, Jiangsu province Lingang Industrial Zone, the south side of the weft Road, eight

Patentee after: Lianyungang Hengyun Pharmaceutical Co. Ltd.

Address before: 222200 Guanyun City, Jiangsu province Lingang Industrial Zone, the south side of the weft Road, eight

Patentee before: Lianyungang Hengyun Pharmaceutical Co. Ltd.